However, the immune responses to the inactivated vaccines, tetanus-diphtheria toxoid (Td), pneumococcal polyvalent vaccine and meningococcal (groups A, C, W-135, and Y) oligosaccharide, were found adequate, and seroprotection levels were achieved in MS patients treated with delayed-release dimethyl fumarate in comparison to patients receiving non-pegylated IFN [66]. This evidence concerns the gene IFNA1 and myeloid sarcoma.